Multidimensional Impact of Mediterranean Diet on IBD Patients

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2020 May 23

PMID 32440680

Citations 90

Authors

Fabio Chicco

Salvatore Magri

Arianna Cingolani

Danilo Paduano

Mario Pesenti

Federica Zara

Francesca Tumbarello

Emanuela Urru

Alessandro Melis

Laura Casula

Massimo Claudio Fantini

Paolo Usai

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Malnutrition with the accumulation of fat tissue and nonalcoholic fatty liver disease (NAFLD) are conditions associated with inflammatory bowel disease (IBD). Visceral fat and NAFLD-related liver dysfunction can both worsen intestinal inflammation. Because the Mediterranean diet (Md) has been shown to ameliorate both obesity and NAFLD, the aim of this study was to analyze the impact of Md on the nutritional state, liver steatosis, clinical disease activity, and quality of life (QoL) in IBD patients.

Methods: Patients with IBD, both Crohn's disease (CD) and ulcerative colitis (UC), followed Md for 6 months. Their body mass index (BMI), body tissue composition, liver steatosis and function, serum lipid profile, clinical disease activity, and inflammatory biomarkers (C-reactive protein and fecal calprotectin) were collected at baseline (T0) and compared with those obtained after 6 months (T180) to evaluate the impact of Md.

Results: One hundred forty-two IBD patients, 84 UC and 58 CD, followed Md for 6 months. At T180, diet-adherent CD and UC improved BMI (UC -0.42, P = 0.002; CD -0.48, P = 0.032) and waist circumference (UC -1.25 cm, P = 0.037; CD -1.37 cm, P = 0.041). Additionally, the number of patients affected by liver steatosis of any grade was significantly reduced in both groups (UC T0 31 of 84 [36.9%] vs T180 18 of 84 [21.4%], P = 0.0016; CD T0 27 of 58 [46.6%] vs T180 18 of 58 [31.0%], P < 0.001) after dietary intervention. Finally, after 6 months of the diet, fewer UC and CD patients with stable therapy had active disease (UC T0 14 of 59 [23.7%] vs T180 4 of 59 [6.8%], P = 0.004; CD T0 9 of 51 [17.6%] vs T180 2 of 51 [3.0%], P = 0.011) and elevated inflammatory biomarkers. Mediterranean diet improved QoL in both UC and CD, but neither serum lipid profile nor liver function were modified by the diet.

Conclusions: A significant reduction of malnutrition-related parameters and liver steatosis was observed in both CD and UC patients after short-term dietary intervention based on the adoption of Md, and this was associated with a spontaneous improvement of disease activity and inflammatory markers.

Citing Articles

From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management.

Naik R, Purcell S, Gold S, Christiansen V, DAloisio L, Raman M Nutrients. 2025; 17(3).

PMID: 39940329 PMC: 11821149. DOI: 10.3390/nu17030470.

Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.

Shneyderman M, Freid H, Kohler D, Peraza J, Haskey N, Abbott E Gastroenterol Hepatol (N Y). 2025; 20(12):712-722.

PMID: 39886003 PMC: 11776002.

Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial.

Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, Cova-Martin R, Goni L, Ballester-Martinez A JMIR Res Protoc. 2025; 14:e64277.

PMID: 39879606 PMC: 11822308. DOI: 10.2196/64277.

Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective.

Qin L, Lv W Nutr J. 2025; 24(1):12.

PMID: 39849464 PMC: 11755847. DOI: 10.1186/s12937-025-01075-y.

Evaluation of dietary quality in patients with functional gastrointestinal symptoms: a Norwegian single centre study.

Holm I, Lorentzen S, Carlsen M, Valeur J, Mellin-Olsen T, Dale H Food Nutr Res. 2025; 68.

PMID: 39781271 PMC: 11708516. DOI: 10.29219/fnr.v68.10692.

References

Mayr H, Itsiopoulos C, Tierney A, Kucianski T, Radcliffe J, Garg M . Ad libitum Mediterranean diet reduces subcutaneous but not visceral fat in patients with coronary heart disease: A randomised controlled pilot study. Clin Nutr ESPEN. 2019; 32:61-69. DOI: 10.1016/j.clnesp.2019.05.001. View

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. View

Walker A, Sanderson J, Churcher C, Parkes G, Hudspith B, Rayment N . High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011; 11:7. PMC: 3032643. DOI: 10.1186/1471-2180-11-7. View

Becker H, Grigat D, Ghosh S, Kaplan G, Dieleman L, Wine E . Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey. Can J Gastroenterol Hepatol. 2015; 29(2):77-84. PMC: 4373565. DOI: 10.1155/2015/815820. View

Panizza C, Lim U, Yonemori K, Cassel K, Wilkens L, Harvie M . Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study. Nutrients. 2019; 11(6). PMC: 6627434. DOI: 10.3390/nu11061386. View

Long M, Crandall W, Leibowitz I, Duffy L, Del Rosario F, Kim S . Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17(10):2162-8. PMC: 3116044. DOI: 10.1002/ibd.21585. View

Palumbo C, Restellini S, Chao C, Aruljothy A, Lemieux C, Wild G . Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis. 2018; 25(1):124-133. DOI: 10.1093/ibd/izy200. View

Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y . Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019; 2019:7659509. PMC: 6613006. DOI: 10.1155/2019/7659509. View

Kolodziejczyk A, Zheng D, Shibolet O, Elinav E . The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2018; 11(2). PMC: 6365925. DOI: 10.15252/emmm.201809302. View

10.

Papada E, Amerikanou C, Forbes A, Kaliora A . Adherence to Mediterranean diet in Crohn's disease. Eur J Nutr. 2019; 59(3):1115-1121. DOI: 10.1007/s00394-019-01972-z. View

11.

Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C . Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol. 2017; 112(12):1832-1839. DOI: 10.1038/ajg.2017.371. View

12.

Agarwal A . Spice up your life: adipose tissue and inflammation. J Lipids. 2014; 2014:182575. PMC: 3950654. DOI: 10.1155/2014/182575. View

13.

Kontogianni M, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D . Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2013; 33(4):678-83. DOI: 10.1016/j.clnu.2013.08.014. View

14.

Bach-Faig A, Berry E, Lairon D, Reguant J, Trichopoulou A, Dernini S . Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011; 14(12A):2274-84. DOI: 10.1017/S1368980011002515. View

15.

Honda K, Littman D . The microbiota in adaptive immune homeostasis and disease. Nature. 2016; 535(7610):75-84. DOI: 10.1038/nature18848. View

16.

Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P . Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504(7480):451-5. PMC: 3869884. DOI: 10.1038/nature12726. View

17.

De Filippis F, Pellegrini N, Vannini L, Jeffery I, La Storia A, Laghi L . High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2015; 65(11):1812-1821. DOI: 10.1136/gutjnl-2015-309957. View

18.

Lomer M, Cahill O, Baschali A, Partha Sarathy P, Sarantidou M, Mantzaris G . A multicentre Study of Nutrition Risk Assessment in Adult Patients with Inflammatory Bowel Disease Attending Outpatient Clinics. Ann Nutr Metab. 2018; 74(1):18-23. DOI: 10.1159/000495214. View

19.

Ananthakrishnan A, Khalili H, Song M, Higuchi L, Richter J, Nimptsch K . High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2015; 21(10):2311-9. PMC: 4567521. DOI: 10.1097/MIB.0000000000000501. View

20.

Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017; 11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008. View